• Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016
Monday Morning
Skip to content
  • Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016

Tag Archives: Tau

Lilly Alzheimer’s drug, like so many others, fails; will true breakthrough happen this century?

Steve Walker    November 28, 2016 May 7, 2018    2 Comments on Lilly Alzheimer’s drug, like so many others, fails; will true breakthrough happen this century?

Eli Lilly & Co. (Indianapolis RIN) said its experimental Alzheimer’s treatment failed to slow loss of cognitive ability in patients with mild symptoms, a major setback for the company and millions of… Read more »

Disease, Pharmaceuticals    Aducanumab, Alzheimer’s Association, Amyloid-Beta, Axovant Sciences Ltd., BACE Inhibitors, Biogen Inc., Clinical Trials on Alzheimer’s Disease, David Ricks, Dementia, Eli Lilly & Co., Evercore ISI, Expedition 3 study, Fortune, GlaxoSmithKline PLC, Intepirdine, John Scotti, Leerink Partners, MarketWatch, Merck & Co., Michael J. Yee, Nilvadipine, RBC Capital Markets, Ronny Gal, Seamus Fernandez, Solanezumab, Tau

Search The Site

Follow @MonMorningNews

Twitter

Tweets by MonMorningNews
Follow me on Blogarama

Facebook

Search The Site

More MondayMorning

  • Recent Posts
  • Most Commented
  • Most Viewed
  • US stock market has a subdued Thanksgiving week, but a slew of healthcare companies rocketed higher.
  • More Chinese medical companies choosing New York over Shanghai, Hong Kong for IPOs; but not always.
  • Health-sector IPO market cools off for Veterans Day breather; but pre-Thanksgiving deals ready to rock.
  • Health-sector IPO market cools off this week after torrid start to November.
    • Insys trial opens with tale of sales rep giving lap dance to doctor for fentanyl prescriptions. News organizations seize upon...
    • Voyager Therapeutics signs another neurodegenerative disease deal with AbbVie that screams “Buy this small cap now.”
    • Little known Czech biotech’s cell therapy greatly increases survival in ovarian cancer. Sotio’s potential breakthrough and another pipeline cancer candidate...
    • It’s time to reclassify schizophrenia as a neurologic disorder.
    Copyright 2018
    Ribosome by GalussoThemes.com
    Powered by WordPress